Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Richard Carvajal MD

Richard D. Carvajal MD

Roy J. and Tara Zuckerberg Professor in Medical Oncology, Deputy Physician-in-Chief, Director of Hematology/Oncology, Northwell Health Cancer Institute, Lake Success, New York

Richard D. Carvajal, MD, is the Roy J. and Tara Zuckerberg Professor in Medical Oncology and the Deputy Physician-in-Chief and Director of Hematology/Oncology at the Northwell Health Cancer Institute. He is recognized as a leader within the melanoma field, with particular expertise in rare melanoma subtypes such as uveal, mucosal and acral melanoma. His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, and the Melanoma Research Foundation. He has authored or co-authored more than 250 peer-reviewed manuscripts, books, and book chapters.

Disclosures

Consulting:

Alkermes, Bristol Myers Squibb, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Trisalus

Clinical/Scientific Advisory Boards:

Aura Biosciences, Chimeron, Rgenix